| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $28.8M | -5.8% | -7.8% |
| SG&A Expense | $7.9M | -7.2% | +11.0% |
| Operating Income | -$36.7M | +6.1% | +4.3% |
| Net Income | -$32.6M | +10.4% | +5.7% |
| EPS (Basic) | -$0.33 | +29.8% | +32.7% |
| EPS (Diluted) | -$0.33 | +29.8% | +32.7% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $49.7M | -34.5% | +12.3% |
| Current Assets | $295.6M | +1.5% | +5.8% |
| Total Assets | $431.2M | +24.3% | +42.7% |
| Current Liabilities | $20.2M | +11.8% | -5.0% |
| Total Liabilities | $24.3M | +6.2% | -13.5% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$88.5M | — | — |
| Capital Expenditures | $485K | — | — |
| Investing Cash Flow | -$165.0M | — | — |
| Financing Cash Flow | $243.8M | — | — |
| Free Cash Flow | -$89.0M | — | — |
| $406.9M |
| +25.6% |
| +48.5% |